In the same direction, Nagasaki et al. showed that in AML patients experiencing post-HSCT relapse, treatment with the combination of AZA+VEN, leads to upregulation of BCL-2 on CD8+ T cells, an increased frequency of cytotoxic CD8+ T cells with high granzyme B and IFN-γ expression, a lower proportion of exhausted PD-1+CD8+ T cells, and an increased frequency of BCL-2high CD8+ Tem cells following treatment compared to baseline [189]. This evidence concerns the gene CD8A and acute myeloid leukemia.